Experimental Ebola drug is hard to make, expert says

An experimental drug given to two American patients with Ebola is made from tobacco leaves and is hard to produce on a large scale, a leading US doctor said Tuesday.

Known as ZMapp, the serum consists of three antibodies manufactured in modified tobacco leaves, which take weeks to grow.

It was reportedly rushed to US missionaries Kent Brantly and Nancy Writebol, who were stricken with Ebola while treating patients in Liberia.

Both have shown improvements in their health and are now being treated in isolation at an Atlanta, Georgia hospital.

"We cannot say right now that this drug is particularly promising," said Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases.

"The animal data are very good and the use of it in the two patients is suggestive that it may have a favorable effect, but since there are only two patients I think you have to be careful about making any definitive decision," he told AFP.

There is no drug or vaccine on the market against Ebola virus, which causes fever, vomiting, diarrhea, muscle aches and sometimes organ failure and hemorrhaging.

The ongoing outbreak in West Africa is the largest in history, having killed 887 of the more than 1,600 infected.

As for ZMapp, which was first identified as a drug candidate in January, there have been no safety tests yet in humans.

"As such, very little of the drug is currently available," the company said in a statement, adding that is working to scale up production as soon as possible.

ZMapp is a project of Mapp Biopharmaceutical, Inc. and LeafBio in San Diego, California, Defyrus Inc. in Toronto, Canada, the US government and the Public Health Agency of Canada.

Fauci said that the process of scaling up production will take time.

"It is going to take several months to get even a modest amount," he said.

"So yes, we do want to do clinical trials but the limiting factor is the number of treatment courses that are available."

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

US approves new, hard-to-abuse hydrocodone pill (Update)

Nov 20, 2014

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

Nov 20, 2014

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

Nov 20, 2014

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

zaxxon451
not rated yet Aug 06, 2014

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.